Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00591890 · ClinicalTrials.gov registry record · Phase 1
Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans
A Phase 1 study, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00591890 is a Phase 1 study that has completed, run by Alaunos Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT00591890, a Phase 1 study, has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Single arm, open label, Phase IB study of indibulin capsules in subjects with advanced solid tumors; eligible subjects will have a baseline PET scan showing a standardized uptake value (SUV) of ≥5.0 in ≥1 lesion on an 18F-FDG (fluorine-18-labeled deoxyglucose) scale.
Interventions
- DRUG indibulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00591890
The ClinicalTrials.gov registry entry for NCT00591890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which indibulin is the first listed.
NCT00591890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00591890 about?
NCT00591890 is a clinical study titled "Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans". Single arm, open label, Phase IB study of indibulin capsules in subjects with advanced solid tumors; eligible subjects will have a baseline PET scan showing a standardized uptake value (SUV) of ≥5.0 in ≥1 lesion on an 18F-FDG (fluorine-18-labeled deoxyglucose) scale.
What is the current status of trial NCT00591890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-10. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00591890?
The interventions under investigation include: indibulin (DRUG).
Who is sponsoring clinical trial NCT00591890?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.